174 related articles for article (PubMed ID: 25179732)
1. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
Yeung DT; Moulton DJ; Heatley SL; Nievergall E; Dang P; Braley J; Branford S; Moore S; Mullighan CG; Hughes TP; White DL
Leukemia; 2015 Jan; 29(1):230-2. PubMed ID: 25179732
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
Takahashi N; Miura M; Scott SA; Niioka T; Sawada K
J Hematol Oncol; 2012 May; 5():23. PubMed ID: 22587422
[TBL] [Abstract][Full Text] [Related]
3. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
5. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
6. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
10. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
[No Abstract] [Full Text] [Related]
11. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
12. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
13. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
14. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Khorashad JS; Milojkovic D; Mehta P; Anand M; Ghorashian S; Reid AG; De Melo V; Babb A; de Lavallade H; Olavarria E; Marin D; Goldman JM; Apperley JF; Kaeda JS
Blood; 2008 Feb; 111(4):2378-81. PubMed ID: 17982022
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
17. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
Loghavi S; Pemmaraju N; Kanagal-Shamanna R; Mehrotra M; Medeiros LJ; Luthra R; Lin P; Huh Y; Kantarjian HM; Cortes JE; Verstovsek S; Patel KP
Blood; 2015 May; 125(21):3360-3. PubMed ID: 25999449
[No Abstract] [Full Text] [Related]
18. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Müller MC; Cortes JE; Kim DW; Druker BJ; Erben P; Pasquini R; Branford S; Hughes TP; Radich JP; Ploughman L; Mukhopadhyay J; Hochhaus A
Blood; 2009 Dec; 114(24):4944-53. PubMed ID: 19779040
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]